Shannon Conley to Genetic Therapy
This is a "connection" page, showing publications Shannon Conley has written about Genetic Therapy.
Connection Strength
2.627
-
Gene therapy for PRPH2-associated ocular disease: challenges and prospects. Cold Spring Harb Perspect Med. 2014 Aug 28; 4(11):a017376.
Score: 0.443
-
Nanoparticles for retinal gene therapy. Prog Retin Eye Res. 2010 Sep; 29(5):376-97.
Score: 0.329
-
Nonviral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther. 2008 Oct; 10(5):456-63.
Score: 0.294
-
Late-onset cone photoreceptor degeneration induced by R172W mutation in Rds and partial rescue by gene supplementation. Invest Ophthalmol Vis Sci. 2007 Dec; 48(12):5397-407.
Score: 0.278
-
Characterization of Ribozymes Targeting a Congenital Night Blindness Mutation in Rhodopsin Mutation. Adv Exp Med Biol. 2016; 854:509-15.
Score: 0.122
-
Non-viral therapeutic approaches to ocular diseases: An overview and future directions. J Control Release. 2015 Dec 10; 219:471-487.
Score: 0.120
-
Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype. FASEB J. 2015 Jun; 29(6):2535-44.
Score: 0.115
-
Episomal maintenance of S/MAR-containing non-viral vectors for RPE-based diseases. Adv Exp Med Biol. 2014; 801:703-9.
Score: 0.106
-
Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol. 2014; 801:719-24.
Score: 0.106
-
A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 2013 Sep; 34(29):7158-67.
Score: 0.102
-
S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA. Hum Mol Genet. 2013 Apr 15; 22(8):1632-42.
Score: 0.099
-
DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest. 2012 Sep; 122(9):3221-6.
Score: 0.096
-
AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci. 2011 May 10; 52(6):3051-9.
Score: 0.088
-
Gene therapy in the Retinal Degeneration Slow model of retinitis pigmentosa. Adv Exp Med Biol. 2010; 664:611-9.
Score: 0.080
-
Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 2010 Apr; 24(4):1178-91.
Score: 0.080
-
RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet. 2009 Jun; 30(2):57-62.
Score: 0.077
-
Nanoparticle applications in ocular gene therapy. Vision Res. 2008 Feb; 48(3):319-24.
Score: 0.068
-
Persistence of non-viral vector mediated RPE65 expression: case for viability as a gene transfer therapy for RPE-based diseases. J Control Release. 2013 Dec 28; 172(3):745-52.
Score: 0.026